Categories Earnings, Health Care

Intercept Pharmaceuticals (NASDAQ: ICPT): Q4 2019 Earnings Snapshot

— Intercept Pharmaceuticals (NASDAQ: ICPT) reported a fourth-quarter 2019 loss of $2.99 per share versus a loss of $2.67 per share expected.

— Total revenue climbed by 34% to $71.5 million versus $68.39 million expected.

Earnings Update by AlphaStreet

— Ocaliva net sales jumped by 33% to $70.3 million from last year. US sales increased by 30% and ex-US sales climbed by 42%.

— Research and development expenses increased by 2% primarily due to increases in development program expenses relating to its lead candidate, obeticholic acid (OCA), for liver fibrosis due to nonalcoholic steatohepatitis (NASH) and costs associated with the submission of new drug application.

— The FDA has set a Prescription Drug User Fee Act target action date of June 26, 2020, for the completion of its review of its NDA seeking approval of obeticholic acid for liver fibrosis due to NASH. The NDA was first accepted by the FDA for live fibrosis due to NASH.

— Looking ahead into full-year 2020, adjusted operating expenses are expected to be $560-600 million. This reflects its investments to support the launch of OCA for liver fibrosis due to NASH, commercial efforts in primary biliary cholangitis, clinical development and pipeline programs and other operating activities.

— During the fourth quarter, the company completed enrollment of Reverse, its phase 3 study evaluating OCA for the treatment of compensated cirrhosis due to NASH.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Salesforce stock hit by weak guidance, co-CEO’s exit. What next?

For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected

Macy’s (M): Here’s a look at the retailer’s expectations for the near term

Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales

KR Earnings: Kroger Q3 sales, profit increase and top expectations

Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top